Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Syno Capital is a global investment firm founded in 2015, headquartered in New York, with additional offices in Hong Kong and Shanghai. The firm specializes in life sciences and healthcare investing, focusing on breakthrough innovations that address pressing healthcare challenges. Since its inception, Syno Capital has established itself as a key player in the healthcare investment space, emphasizing scientific research and data-driven decision-making.
As of now, Syno Capital manages a portfolio of six companies, reflecting a selective investment strategy. The firm is dedicated to supporting companies that are poised to make a significant impact in the healthcare sector. Notable milestones include their involvement in the funding of ORIG3N, a biotech firm recognized for developing treatments for rare and genetically inherited diseases.
Syno Capital's commitment to bridging the US and Greater China healthcare markets is a distinctive aspect of its investment strategy. The firm collaborates with leading minds in the healthcare industry to tackle pressing challenges, leveraging its cross-border expertise and network in both regions.
Syno Capital invests primarily in healthcare innovations, with a disciplined approach guided by scientific research. The firm focuses on three main sectors: therapeutics, medical devices, and digital health. This strategic focus aims to tackle significant challenges in the healthcare industry, particularly those that can lead to transformative outcomes for patients and healthcare providers.
The firm seeks to support companies that are not only innovative but also capable of making a substantial impact in the healthcare sector. Syno Capital emphasizes the importance of data-driven decision-making in its investment process, ensuring that each investment aligns with rigorous scientific standards. Additionally, the firm facilitates the expansion of US portfolio companies into the Greater China region, enhancing their market reach and growth potential.
Syno Capital's portfolio consists of six companies, with a notable focus on healthcare innovations. One of the key portfolio companies is ORIG3N, a biotech firm that develops treatments for rare and genetically inherited diseases. ORIG3N operates the world's largest induced pluripotent stem cell (iPSC) bank, positioning itself as a leader in the biotech space.
While specific details about the other five portfolio companies are not disclosed, Syno Capital's investment strategy emphasizes sectors such as therapeutics, medical devices, and digital health. This focus aligns with the firm's mission to address significant healthcare challenges through innovative solutions.
To pitch to Syno Capital, founders should visit the firm's website at synocapital.com. It is recommended to include a comprehensive pitch deck that outlines the company's innovation, market opportunity, and scientific validation. The firm appreciates detailed information that demonstrates a clear understanding of the healthcare landscape.
Response times may vary, but founders should expect a thorough review process given the firm's selective investment strategy. Warm introductions can enhance the chances of securing a meeting, as Syno Capital values connections within the healthcare community.
What are Syno Capital's investment criteria?
Syno Capital focuses on healthcare innovations, particularly in therapeutics, medical devices, and digital health. The firm seeks companies that demonstrate a strong potential for impact and are guided by scientific research.
How can founders pitch to Syno Capital?
Founders can submit their pitches through the firm's website at synocapital.com. It is advisable to include detailed information about the company's innovation, market potential, and scientific backing in the pitch deck.
What makes Syno Capital different from other venture firms?
Syno Capital differentiates itself by emphasizing a cross-border investment strategy that bridges the US and Greater China healthcare markets. This unique approach allows portfolio companies to expand their reach and leverage opportunities in both regions.
What is the typical check size for investments?
While specific check sizes are not publicly disclosed, Syno Capital invests across seed, early, and later stages, indicating a flexible approach to funding based on the company's needs and growth stage.
What is Syno Capital's involvement post-investment?
Syno Capital actively supports its portfolio companies, particularly in facilitating their expansion into the Greater China market. The firm leverages its network and expertise to assist in navigating the complexities of cross-border operations.
What is the fund size of Syno Capital?
The fund size has not been publicly disclosed, but the firm has made six investments since its founding in 2015, indicating a selective investment strategy.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.